<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ISTA Pharmaceuticals Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/ista-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ARQL) Company News for January 18, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416</link>
		<comments>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:42:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Blackbaud Inc]]></category>
		<category><![CDATA[BLKB]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Venoco Inc]]></category>
		<category><![CDATA[VQ]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90416</guid>
		<description><![CDATA[•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company&#8217;s experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a secondary offering •    Global provider of software Blackbaud Inc. (NASDAQ:BLKB) will buy fund raising software maker Convio Inc. (NASDAQ:CNVO) for $16 per share. Following the news, shares of Convio rocketed up 48% to close at $15.89 a share •    ISTA Pharmaceuticals Inc.’s shares (NASDAQ:ISTA) gained 13.07% after Valeant Pharmaceuticals International Inc. (NYSE:VRX) increased its hostile-takeover bid for ISTA to $7.50 a share •    Shares of natural gas firm Venoco Inc. (NYSE:VQ) surged 29.91% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADBE) Company News for December 19, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857</link>
		<comments>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857#comments</comments>
		<pubDate>Mon, 19 Dec 2011 19:51:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Application Software]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ADBE]]></category>
		<category><![CDATA[Adobe Systems Inc.]]></category>
		<category><![CDATA[Cablevision Systems Corporation]]></category>
		<category><![CDATA[CVC]]></category>
		<category><![CDATA[Darden Restaurants Inc.]]></category>
		<category><![CDATA[DRI]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88857</guid>
		<description><![CDATA[•    Zynga, Inc. (NASDAQ:ZNGA) made its debut on the Nasdaq and dropped 5.0% to $9.50. The company’s initial public offering was priced at $10.00 per share •    Shares of Adobe Systems Inc. (NASDAQ:ADBE) jumped 6.6% a day after reporting fully diluted pro forma earnings per share of $0.55, topping the Zacks Consensus Estimate of $0.50 per share •    United Rentals, Inc.’s (NYSE:URI) $1.9 billion acquisition bid for RSC Holdings, Inc. (NYSE:RRR) helped RSC’s shares gain a whopping 57.9% •    Shares of Cablevision Systems Corporation (NYSE:CVC) plummeted 8.5% after the company said that its chief operating officer has planned to vacate office this month •    Valeant Pharmaceuticals International, Inc.’s (NYSE:VRX) acquisition offer of ISTA Pharmaceuticals Inc. (NASDAQ:ISTA) for $6.50 per share took the latter’s stocks up by 71.7% •    Darden Restaurants, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709</link>
		<comments>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709#comments</comments>
		<pubDate>Wed, 09 Sep 2009 22:24:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14709</guid>
		<description><![CDATA[Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a twice-daily prescription eye drop treatment. ISTA filed the New Drug Application for the drug (bepotastine ophthalmic solution) on Nov 13, 2008. As a reminder, the advisory committee of the FDA had recommended the drug in June. The seven-member panel had voted unanimously in favor of Bepreve after reviewing comprehensive safety and efficacy data from ISTA&#8217;s clinical program. Bepreve is expected to be available to ophthalmologists and patients in the United States in the fourth quarter of 2009. The company, which expects to recognize revenues from the drug from this ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals&#8217;s Eye Drug Shows Success</title>
		<link>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559</link>
		<comments>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559#comments</comments>
		<pubDate>Thu, 27 Aug 2009 19:51:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13559</guid>
		<description><![CDATA[ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market. The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

